Edit
LifeSpan Vision Ventures
https://www.lifespanvisionventures.com/Last activity: 21.02.2026
Active
Lifespan Vision Ventures invests in companies that develop diagnostics and therapeutics focusing on longevity and aging reversal. Our goal is to enable healthy, strong, and vibrant human lifespan past 120 years. Our primary foci are joints, heart, skin, and muscles.
Investment Stage: Seed
Portfolio 1
| Date | Name | Website | Total Raised | Location |
| 09.01.2026 | TECregen | tecregen.com | $12.53M | - |
Mentions in press and media 8
| Date | Title | Description |
| 21.02.2026 | Sift Biosciences Raises $3.7 Million Pre-Seed To Advance T-Cell Booster Platform | Sift Biosciences has closed an oversubscribed $3.7 million pre-seed financing round to accelerate development of its next-generation peptide immunotherapy platform designed to activate pre-existing memory T cells. The round was co-led by Fr... |
| 19.02.2026 | Sift Biosciences Raises $3.7M in Pre-Seed Funding | Sift Biosciences, a San Carlos, CA-based provider of a peptide-based immunotherapy platform, raised $3.7M in Pre-Seed funding. The round was co-led by Lifespan Vision Ventures and Freeflow Ventures, with participation from Valuence Ventures... |
| 14.01.2026 | TECregen Secures CHF 10 Million, Appoints Chairman to Propel Immune Rejuvenation | Swiss biotech TECregen secured CHF 10 million in seed funding. This investment propels its pioneering thymus-rejuvenating biologics. The goal: restore robust immune function, counter age-related decline, and tackle serious diseases. Boehrin... |
| 09.01.2026 | CHF 10 million seed funding and new board chair for TECregen | Alongside the Boehringer Ingelheim Venture Fund (BIVF) TECregen’s funding round saw participation from LifeSpan Vision Ventures, Carma Fund, EOS BioInnovation, High-Tech Gründerfonds (HTGF), the JFG Life Sciences Foundation of the Univers... |
| 08.01.2026 | TECregen Raises CHF 10 Million Seed Round, Names Dr. Bo Rode Hansen Chairman | Basel, Switzerland-based TECregen has raised CHF 10 million (approximately €10.7 million / $12.6 million) in seed financing to advance a new class of thymus-rejuvenating biologics aimed at restoring immune function by rejuvenating thymic ep... |
| 11.11.2024 | EpiBone: Pioneering the Future of Skeletal Repair | EpiBone is on a mission. This New York City-based company is not just another name in the crowded field of regenerative medicine. It’s a beacon of hope for those suffering from skeletal injuries and diseases. Recently, EpiBone secured a sig... |
| 11.11.2024 | EpiBone Raises Funding Round | EpiBone, a NYC-based regenerative medicine company, raised an undisclosed amount in funding. The round was led by Kendall Capital Partners, with participation from LifeSpan Vision Ventures, EMV Capital, and others. The company intends to us... |
| 08.11.2024 | EpiBone: Regenerative Medicine Company Raises Funding | EpiBone – a leading regenerative medicine company focused on skeletal repair – announced the closing of a convertible note funding round led by Kendall Capital Partners, with participation from LifeSpan Vision Ventures, EMV Capital, and oth... |